Literature DB >> 1702032

Association between allo-immunoreactive and xeno-immunoreactive subunits of a glycoprotein tumor-associated antigen.

D M Euhus1, R K Gupta, D L Morton.   

Abstract

Using allogeneic antibody, we previously described a tumor-associated antigen (TAA) in the urine of 68% of melanoma patients. The TAA was purified from urine of a melanoma patient and used as immunogen to develop a murine monoclonal antibody (AD1-40F4) and xenopolyclonal antibodies in a baboon. Sera from melanoma patients treated with whole melanoma cell vaccine were used as the source of human antibody to the glycoprotein antigen. Treatment with 2-mercaptoethanol and separation by sodium dodecyl sulfate/polyacrylamide gel electrophoresis resolved the high-molecular-mass glycoprotein TAA into smaller subunits. Immunoblot analysis indicates that the murine monoclonal antibody (AD1-40F4) recognized a 90-100-kDa subunit of the antigen while human anti-TAA antibodies primarily recognized a 65-kDa subunit in addition to the 90-100-kDa subunit. Baboon polyclonal antibodies recognized the same subunits plus a 120-kDa subunit. Blocking studies indicated that the murine monoclonal and baboon polyclonal antibodies recognized the closely related epitopes on the 90-100-kDa subunit, while human antibodies recognized an epitope entirely distinct from that recognized by the mouse antibody. These results demonstrate the epitope complexity associated with the high-molecular-mass glycoprotein TAA.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1702032     DOI: 10.1007/bf01741703

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  16 in total

1.  Characterization of a 90-100 kDa tumor-associated antigen in the sera of melanoma patients.

Authors:  D M Euhus; R K Gupta; D L Morton
Journal:  Int J Cancer       Date:  1990-06-15       Impact factor: 7.396

2.  Detection of immunoglobulin G antibodies in melanoma sera reactive with intracellular proteins.

Authors:  E Bonfa; J C Bystryn; K B Elkon
Journal:  J Invest Dermatol       Date:  1988-02       Impact factor: 8.551

3.  Common human melanoma-associated antigen(s) detected by monoclonal antibodies.

Authors:  S Carrel; R S Accolla; A L Carmagnola; J P Mach
Journal:  Cancer Res       Date:  1980-07       Impact factor: 12.701

4.  Tumor-associated antigens detected by autologous sera in urine of patients with solid neoplasms.

Authors:  N S Rote; R K Gupta; D L Morton
Journal:  J Surg Res       Date:  1980-07       Impact factor: 2.192

5.  AU cell-surface antigen of human malignant melanoma: solubilization and partial characterization.

Authors:  T E Carey; K O Lloyd; T Takahashi; L R Travassos; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1979-06       Impact factor: 11.205

6.  Detection of a tumor-associated glycoprotein antigen in serum and urine of melanoma patients by murine monoclonal antibody (AD1-40F4) in enzyme immunoassay.

Authors:  D M Euhus; R K Gupta; D L Morton
Journal:  J Clin Lab Anal       Date:  1989       Impact factor: 2.352

Review 7.  Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture.

Authors:  L J Old
Journal:  Cancer Res       Date:  1981-02       Impact factor: 12.701

8.  Monoclonal antibodies to 125 kd and 95 kd proteins on human melanoma cells: comparison with other monoclonal-defined melanoma antigens.

Authors:  R E Saxton; B D Mann; D L Morton; M W Burk
Journal:  Hybridoma       Date:  1982

9.  Isolation and partial characterization of melanoma-associated antigens identified by autologous antibody.

Authors:  D R Vlock; D Scalise; N Meglin; J M Kirkwood; B Ballou
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

10.  Class 1 (unique) tumor antigens of human melanoma. Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody.

Authors:  F X Real; M J Mattes; A N Houghton; H F Oettgen; K O Lloyd; L J Old
Journal:  J Exp Med       Date:  1984-10-01       Impact factor: 14.307

View more
  1 in total

1.  Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model.

Authors:  R C Jones; M Kelley; R K Gupta; J A Nizze; R Yee; Z Leopoldo; K Qi; S Stern; D L Morton
Journal:  Ann Surg Oncol       Date:  1996-09       Impact factor: 5.344

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.